No Data
Phio Pharma Analyst Ratings
Positive Outlook for Phio Pharmaceuticals: Promising Clinical Results and Innovative Technology Drive Buy Rating
H.C. Wainwright Maintains Phio Pharmaceuticals(PHIO.US) With Buy Rating, Cuts Target Price to $4
Phio Pharmaceuticals Showcases New Cancer-Fighting Gene Therapy at Industry Event
Express News | Phio Pharmaceuticals Corp Files for Offering of up to 5.93 Mln Common Shares by the Selling Stockholders - SEC Filing
Optinose OPTN +20% Preliminary Product Revenue; Phio Pharmaceuticals PHIO -26% Offering
